Lipoprotein(a) and its Lipid Cargo in the era of Lp(a) Inhibitors

Tuesday, July 28
6:00 – 7:30 p.m.
Hilton Anaheim, California A
Presented by Helena Laboratories Corporation

Overview

Lipoprotein(a) [Lp(a)] is a genetically determined contributor to atherosclerotic cardiovascular disease. The emergence of the first Lp(a)-specific pharmacotherapies in late-stage clinical trials, along with the endorsement of one-time universal Lp(a) measurement in most major global guidelines, is expected to significantly increase Lp(a) test utilization.

However, accurate measurement of Lp(a) is complicated by its size heterogeneity across the population. Additionally, it is often underrecognized that the cholesterol contained within Lp(a) is included in reported LDL-C values as part of a standard lipid panel. This can lead to challenges in diagnosis and treatment monitoring for certain patients. This workshop will explore these important considerations.

Outcome

1. Comprehend the latest national and international guidelines supporting Lp(a) testing and how to interpret results.

2. Understand how Lp(a) cholesterol contributes to reported LDL-C in the lipid panel and how Lp(a)-C can complicate LDL-C interpretation.

Moderator

Robert S. Galen, MD, MPH
Professor Emeritus, Epidemiology & Biostatistics
University of Georgia College of Public Health

Speakers

Leslie J. Donato, PhD
Co-Director, Hospital Clinical Laboratory, Division of Clinical Core Laboratory Services
Mayo Clinic

Vlad C. Vasile, MD, PhD
Assistant Professor, Laboratory Medicine and Pathology; Consultant, Division of Preventive Cardiology
Mayo Clinic